EMERYVILLE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of management will participate on panels and host investor meetings at two conferences in April: Stifel First Annual CNS Day and William Blair 3rd Annual Late-Stage Therapeutics Conference.
| Stifel First Annual CNS Day | |
| Date: | Monday, April 1, 2019 |
| Location: | The Four Seasons Hotel, Boston |
| Panel: | Future of Epilepsy Treatment |
| Participant: | Stephen J. Farr, President and Chief Executive Officer |
| Time: | 3:35 PM Eastern Time / 12:35 PM Pacific Time |
| William Blair 3rd Annual Late-Stage Therapeutics Conference | |
| Date: | Thursday, April 4, 2019 |
| Location: | Omni Berkshire Place, New York |
| Panel: | New Therapies for Epileptic Disorders |
| Participant: | Gail Farfel, Ph.D., Executive Vice President & Chief Development Officer |
| Time: | 8:00 AM Eastern Time / 5:00 AM Pacific Time |
About Zogenix
Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company’s lead candidate, FINTEPLA® (ZX008, fenfluramine) has been accepted for review by the European Medicines Agency; is awaiting an acceptance decision by the U.S. Food & Drug Administration; and is in development in Japan. For more information, visit www.zogenix.com.
CONTACT:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
media@zogenix.com
Media
Rachel Lipsitz
Public Relations, Syneos Health
+1 (858) 449 9575 | rachel.lipsitz@syneoshealth.com
Investors
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
+1 (646) 597-6987 | Andrew@lifesciadvisors.com